rss
Ann Rheum Dis 65:465-470 doi:10.1136/ard.2005.048637
  • Extended report

Methotrexate modulates the kinetics of adenosine in humans in vivo

  1. N P Riksen1,2,
  2. P Barrera3,
  3. P H H van den Broek1,
  4. P L C M van Riel3,
  5. P Smits1,2,
  6. G A Rongen1,2
  1. 1Department of Pharmacology-Toxicology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Yhe Netherlands
  2. 2Department of Internal Medicine, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, The Netherlands
  3. 3Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, The Netherlands
  1. Correspondence to:
    Dr N P Riksen
    Department of Pharmacology-Toxicology 149, Radboud University Nijmegen Medical Centre, Geert Grooteplein 21, 6525 EZ Nijmegen, The Netherlands; N.Riksen{at}aig.umcn.nl
  • Accepted 19 November 2005
  • Published Online First 24 November 2005

Abstract

Background: Animal studies suggest that the anti-inflammatory effect of methotrexate (MTX) is mediated by increased adenosine concentrations.

Objective: To assess the effect of MTX on the vasodilator effects of adenosine and the nucleoside uptake inhibitor, dipyridamole, in humans in vivo as a marker for changes in adenosine kinetics.

Methods: Ten patients with active arthritis were treated with MTX (15 mg/week). Measurements were performed before and after 12 weeks of treatment. At these time points, the activity of adenosine deaminase was measured in isolated lymphocytes, and forearm blood flow (FBF) was determined by venous occlusion plethysmography during administration of adenosine and dipyridamole into the brachial artery.

Results: The Vmax of adenosine deaminase in lymphocytes was reduced by MTX treatment (p<0.05). MTX significantly enhanced vasodilator response to adenosine (0.5 and 1.5 μg/min/dl of forearm tissue; mean (SE) FBF ratio increased from 1.2 (0.2) to 1.4 (0.2) and 2.2 (0.2) ml/dl/min, respectively, before and from 1.3 (0.1) to 1.8 (0.2) and 3.2 (0.5) ml/dl/min during MTX treatment; p<0.05). Also, dipyridamole-induced vasodilatation (30 and 100 μg/min/dl) was enhanced by MTX (FBF ratio increased from 1.2 (0.2) to 1.5 (0.3) and 1.8 (0.2), respectively, before and from 1.3 (0.1) to 1.8 (0.2) and 2.4 (0.4) during MTX treatment; p<0.05).

Conclusions: MTX treatment inhibits deamination of adenosine and potentiates adenosine-induced vasodilatation. Also dipyridamole-induced vasodilatation is enhanced by MTX treatment, suggesting an increased extracellular formation of adenosine. These effects on the adenosine kinetics in humans may contribute to the therapeutic efficacy of MTX.

Footnotes

  • Published Online First 24 January 2006

  • Conflict of interest: None.